Details about Adrian Towse
Access statistics for papers by Adrian Towse.
Last updated 2018-04-23. Update your information in the RePEc Author Service.
Short-id: pto443
Jump to Journal Articles Books
Working Papers
2018
- Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
Consulting Reports, Office of Health Economics
- Real World Evidence for Coverage Decisions: Opportunities and Challenges
Research Papers, Office of Health Economics View citations (6)
- Review of CRA's Report "Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe"
Consulting Reports, Office of Health Economics
- Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
Research Papers, Office of Health Economics
2017
- 'Macro' Evaluation of the NIHR Oxford Biomedical Research Centre
Research Papers, Office of Health Economics
- Additional Elements of Value for Health Technology Assessment Decisions
Briefings, Office of Health Economics View citations (3)
- Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
Briefings, Office of Health Economics
- Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
Briefings, Office of Health Economics View citations (1)
- Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
Consulting Reports, Office of Health Economics View citations (3)
- Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
Research Papers, Office of Health Economics View citations (2)
- HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
Briefings, Office of Health Economics
- How can HTA meet the needs of health system and government decision makers?
Briefings, Office of Health Economics
- Incentives for New Drugs to Tackle Anti-Microbial Resistance
Briefings, Office of Health Economics View citations (2)
- Policy Options for Formulary Development in Middle-income Countries
Consulting Reports, Office of Health Economics View citations (1)
- Transferability of HTA
Briefings, Office of Health Economics View citations (1)
2016
- Four Case Studies to Explore the Added Value of Oxford AHSN
Consulting Reports, Office of Health Economics
- How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
Briefings, Office of Health Economics
- Improving Efficiency and Resource Allocation in Future Cancer Care
Consulting Reports, Office of Health Economics
- Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
Consulting Reports, Office of Health Economics View citations (1)
- Uncertainty and Risk in HTA Decision Making
Research Papers, Office of Health Economics View citations (3)
2015
- Data Governance Arrangements for Real-World Evidence
Consulting Reports, Office of Health Economics View citations (2)
- International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa
Occasional Papers, Office of Health Economics
- Multi-indication Pricing: Pros, Cons and Applicability to the UK
Seminar Briefings, Office of Health Economics View citations (7)
2014
- Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
Occasional Papers, Office of Health Economics
- The Expanding Value Footprint of Oncology Treatments
Consulting Reports, Office of Health Economics View citations (4)
- What is the Role of HTA for Biosimilars?
Briefings, Office of Health Economics View citations (2)
2013
- Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
Occasional Papers, Office of Health Economics View citations (12)
- Exploring the link between health and wealth in decision making
Research Papers, Office of Health Economics
2012
- Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
Research Papers, Office of Health Economics View citations (4)
- The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
Occasional Papers, Office of Health Economics View citations (2)
- Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
See also Journal Article in Health Economics (2015)
2011
- Incentives for R&D for New Antimicrobial Drugs
Research Papers, Office of Health Economics View citations (1)
See also Journal Article in International Journal of the Economics of Business (2011)
- Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
Research Papers, Office of Health Economics View citations (1)
- Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
See also Journal Article in Health Economics (2015)
- Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
Occasional Papers, Office of Health Economics View citations (2)
- The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
Consulting Reports, Office of Health Economics View citations (6)
2010
- New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
Occasional Papers, Office of Health Economics View citations (1)
- Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
Consulting Reports, Office of Health Economics View citations (1)
- Using QALYs in Cancer: Review of the Methodological Limitations
Research Papers, Office of Health Economics View citations (11)
2009
- Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience
Consulting Reports, Office of Health Economics
2008
- The Market for Biosimilars: Evolution and Policy Options
Briefings, Office of Health Economics View citations (8)
2006
- Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
Consulting Reports, Office of Health Economics
- Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
Briefings, Office of Health Economics
2003
- Reducing Harm to Patients in the National Health Service. Will the Government's Compensation Proposals Help?
Briefings, Office of Health Economics View citations (1)
1998
- From Efficacy to Cost-Effectiveness
Briefings, Office of Health Economics View citations (3)
1997
- Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
Briefings, Office of Health Economics View citations (2)
Journal Articles
2017
- Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
Health Policy, 2017, 121, (10), 1025-1030 View citations (5)
2016
- Biosimilars: How Can Payers Get Long-Term Savings?
PharmacoEconomics, 2016, 34, (6), 609-616 View citations (7)
- Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
Oxford Review of Economic Policy, 2016, 32, (1), 64-87
2015
- European Union Pharmaceutical Markets: A Case for Differential Pricing?
International Journal of the Economics of Business, 2015, 22, (2), 263-275 View citations (6)
- Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
Health Economics, 2015, 24, (2), 238-252 View citations (10)
See also Working Paper (2011)
- Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
Health Economics, 2015, 24, (3), 294-301 View citations (12)
See also Working Paper (2012)
2014
- Orphan drugs policies: a suitable case for treatment
The European Journal of Health Economics, 2014, 15, (4), 335-340 View citations (10)
2013
- Operationalizing Value-Based Pricing of Medicines
PharmacoEconomics, 2013, 31, (1), 1-10 View citations (13)
2012
- Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
The European Journal of Health Economics, 2012, 13, (1), 1-5 View citations (13)
2011
- Incentives for R&D for New Antimicrobial Drugs
International Journal of the Economics of Business, 2011, 18, (2), 331-350 View citations (1)
See also Working Paper (2011)
2006
- The desirability and feasibility of economic studies of drugs post-launch
The European Journal of Health Economics, 2006, 7, (1), 5-6 View citations (1)
2004
- Genetic screening, health care and the insurance industry
The European Journal of Health Economics, 2004, 5, (2), 116-121 View citations (2)
1999
- Is disease management relevant in Europe: some evidence from the United Kingdom
Health Policy, 1999, 48, (1), 69-77
- Medical negligence and the NHS: an economic analysis
Health Economics, 1999, 8, (2), 93-101 View citations (6)
1994
- The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8
Health Economics, 1994, 3, (5), 347-348
Books
2012
- The R&D Cost of a New Medicine
Monographs, Office of Health Economics View citations (25)
2011
- New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
Monographs, Office of Health Economics View citations (4)
2010
- Biosimilars: How Much Entry and Price Competition Will Result?
Monographs, Office of Health Economics View citations (4)
2008
- The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way
Monographs, Office of Health Economics View citations (1)
2006
- Economic Post-Launch Studies: Matching the Desirable with the Feasible
Monographs, Office of Health Economics View citations (1)
2002
- Cost-Effectiveness Thresholds: Economic and ethical issues
Monographs, Office of Health Economics View citations (21)
- Influencing Prescribing in a Primary Care Led NHS
Monographs, Office of Health Economics
- Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
Monographs, Office of Health Economics View citations (4)
1999
- Disease Management, the NHS and the Pharmaceutical Industry
Monographs, Office of Health Economics
1997
- Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
Monographs, Office of Health Economics View citations (4)
1995
- Financing Health Care in the UK: A Discussion of NERA's Prototype Model to Replace the NHS
Monographs, Office of Health Economics View citations (2)
- Industrial Policy and the Pharmaceutical Industry
Monographs, Office of Health Economics View citations (2)
- Value of the Pharmaceutical Industry to the UK Economy
Monographs, Office of Health Economics View citations (1)
|
The links between different versions of a paper are constructed automatically by matching on the titles.
Please contact if a link is incorrect.
Use this form
to add links between versions where the titles do not match.
|